ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Price & Overview
FRA:DUL • US02043Q1076
Current stock price
The current stock price of DUL.DE is 263.6 EUR. Today DUL.DE is down by -6.23%. In the past month the price decreased by -9.2%.
DUL.DE Key Statistics
- Market Cap
- 35.172B
- P/E
- 155.98
- Fwd P/E
- 45.23
- EPS (TTM)
- 1.69
- Dividend Yield
- N/A
DUL.DE Stock Performance
DUL.DE Stock Chart
DUL.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DUL.DE.
DUL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DUL.DE. DUL.DE has an average financial health and profitability rating.
DUL.DE Earnings
On February 12, 2026 DUL.DE reported an EPS of 0.82 and a revenue of 1.10B. The company missed EPS expectations (-28.48% surprise) and missed revenue expectations (-8.27% surprise).
DUL.DE Forecast & Estimates
36 analysts have analysed DUL.DE and the average price target is 381.27 EUR. This implies a price increase of 44.64% is expected in the next year compared to the current price of 263.6.
For the next year, analysts expect an EPS growth of 244.73% and a revenue growth 48% for DUL.DE
DUL.DE Groups
Sector & Classification
DUL.DE Financial Highlights
Over the last trailing twelve months DUL.DE reported a non-GAAP Earnings per Share(EPS) of 1.69. The EPS increased by 191.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.45% | ||
| ROA | 6.32% | ||
| ROE | 39.76% | ||
| Debt/Equity | 3.14 |
DUL.DE Ownership
DUL.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.36 | 42.177B | ||
| ARGX | ARGENX SE | 29.03 | 42.115B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.152B | ||
| ABVX | ABIVAX SA | N/A | 7.663B | ||
| 2X1 | ABIVAX SA | N/A | 7.651B | ||
| GLPG | GALAPAGOS NV | N/A | 1.609B | ||
| GXE | GALAPAGOS NV | N/A | 1.604B | ||
| NANO | NANOBIOTIX | N/A | 1.373B | ||
| PHARM | PHARMING GROUP NV | 46.75 | 1.006B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 977.565M | ||
| PHGN | PHARMING GROUP NV | 45.53 | 969.681M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 900.423M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DUL.DE
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
IPO: 2004-05-28
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS US
Employees: 2500
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / DUL.DE FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the current price of DUL stock?
The current stock price of DUL.DE is 263.6 EUR. The price decreased by -6.23% in the last trading session.
Does ALNYLAM PHARMACEUTICALS INC pay dividends?
DUL.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of DUL stock?
DUL.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the Price/Earnings (PE) ratio of ALNYLAM PHARMACEUTICALS INC (DUL.DE)?
The PE ratio for ALNYLAM PHARMACEUTICALS INC (DUL.DE) is 155.98. This is based on the reported non-GAAP earnings per share of 1.69 and the current share price of 263.6 EUR.